Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Preferred Stock Liabilities (2016 - 2025)

Wave Life Sciences (WVE) has disclosed Preferred Stock Liabilities for 11 consecutive years, with $7.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Preferred Stock Liabilities changed 0.0% year-over-year to $7.9 million, compared with a TTM value of $7.9 million through Dec 2025, changed 0.0%, and an annual FY2025 reading of $7.9 million, changed 0.0% over the prior year.
  • Preferred Stock Liabilities was $7.9 million for Q4 2025 at Wave Life Sciences, roughly flat from $7.9 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $7.9 million in Q1 2021 and bottomed at $7.9 million in Q1 2021.
  • Average Preferred Stock Liabilities over 5 years is $7.9 million, with a median of $7.9 million recorded in 2021.
  • Peak annual rise in Preferred Stock Liabilities hit 0.0% in 2021, while the deepest fall reached 0.0% in 2021.
  • Year by year, Preferred Stock Liabilities stood at $7.9 million in 2021, then changed by 0.0% to $7.9 million in 2022, then changed by 0.0% to $7.9 million in 2023, then changed by 0.0% to $7.9 million in 2024, then changed by 0.0% to $7.9 million in 2025.
  • Business Quant data shows Preferred Stock Liabilities for WVE at $7.9 million in Q4 2025, $7.9 million in Q3 2025, and $7.9 million in Q2 2025.